Apalutamide
Non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer
- CAS No.
- 956104-40-8
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Urology
- Target / Mechanism
- AR
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 3 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| 1-amino-N-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]Cyclobutanecarboxamide | 1950587-17-3 | — | |
| 5-Amino-3-(trifluoromethyl)picolinonitrile | 573762-62-6 | — | |
| N-Boc-1-aminocyclobutanecarboxylic acid | 120728-10-1 | — |
Listing Logic · Why It's Worth Listing
A core endocrine therapy for prostate cancer requiring continuous long-term dosing, ensuring stable annual API demand and well suited to long-term FSO supply arrangements.
Oncology / Urology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
3 key intermediates available; scale-up and cost control manageable
Product Description
Apalutamide is a prescription medication used to treat non-metastatic, castration-resistant prostate cancer. It works by blocking the hormones that fuel cancer growth, helping to delay the spread of cancer and improve outcomes.
Supply source: Unibest · Apalutamide, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.